DARE

Daré Bioscience, Inc.

NasdaqCMUSDEQUITY DELAYED

0.82

▲ 0.01 (0.73%)

MARKET · —

Price

Open

0.78

Prev close

0.81

Day high

0.85

Day low

0.80

Volume

345.54K

Market cap

—

P/E (TTM)

—

52W range

0.75 – 3.78

Trailing performance

Price return · vs SPY

Returnvs SPY

-11.83% -10.5%

-34.92% -38.7%

-65.98% -69.1%

-50.30% -61.4%

YTD

-57.51% -69.8%

-60.19% -80.2%

-90.64% -164.8%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

1.06

-22.89% from price

SMA 20

1.17

-29.87% from price

SMA 50

1.62

-49.51% from price

SMA 100

1.95

-58.14% from price

SMA 200

1.87

-56.22% from price

EMA 12

1.03

-20.64% from price

EMA 26

1.25

-34.79% from price

EMA 50

1.50

-45.68% from price

RSI (14)

26.8

Oversold

MACD (12,26,9)

-0.22

Hist -0.03

ATR (14)

0.14

17.11% of price

Realised vol 30D

168.7%

Annualised

Bollinger upper

1.64

20, 2σ

Bollinger lower

0.70

20, 2σ

50 / 200 cross

Death

1.62 vs 1.87

Trend bias

Below 200

-56.22%

Risk profile

Daily returns · 1Y window

Beta vs SPY

1.07

More volatile than market

Correlation to SPY

0.13

Largely independent

Realised vol 30D

168.7%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-76.5%

Peak to trough

Max drawdown 5Y

-97.0%

Peak to trough

ATR 14

0.14

17.11% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 0.82

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

DARE · links out to the publisher

Daré Bioscience (DARE) Q2 2026 Earnings Call Transcript Motley Fool · 2d ago DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List GlobeNewswire · 4d ago Dare Bioscience Inc (DARE) (Q2 2026) Earnings Call Highlights: Commercial Launch Milestones and ... GuruFocus.com · 5d ago Dare Bioscience Prices $6 Million Registered Direct Offering; Shares Fall MT Newswires · 8d ago Daré Bioscience Announces Pricing of $6.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules GlobeNewswire · 8d ago Daré Bioscience, Inc. Q2 2026 Earnings Call Summary Moby · 8d ago Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Beats Revenue Estimates Zacks · 9d ago Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances GlobeNewswire · 9d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.